BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

532 related articles for article (PubMed ID: 10836293)

  • 21. Clinicopathologic and Molecular Features of Paired Cases of Metachronous Ovarian Serous Borderline Tumor and Subsequent Serous Carcinoma.
    Chui MH; Xing D; Zeppernick F; Wang ZQ; Hannibal CG; Frederiksen K; Kjaer SK; Cope L; Kurman RJ; Shih IM; Wang TL; Vang R
    Am J Surg Pathol; 2019 Nov; 43(11):1462-1472. PubMed ID: 31343420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serous and mucinous borderline ovarian tumours: differences in clinical presentation, high-risk histopathological features, and lethal recurrence rates.
    Vasconcelos I; Darb-Esfahani S; Sehouli J
    BJOG; 2016 Mar; 123(4):498-508. PubMed ID: 26705090
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ovarian papillary serous tumors of low malignant potential (serous borderline tumors). A long-term follow-up study, including patients with microinvasion, lymph node metastasis, and transformation to invasive serous carcinoma.
    Kennedy AW; Hart WR
    Cancer; 1996 Jul; 78(2):278-86. PubMed ID: 8674004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases.
    Parker RL; Clement PB; Chercover DJ; Sornarajah T; Gilks CB
    Int J Gynecol Pathol; 2004 Jul; 23(3):265-72. PubMed ID: 15213603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Classification of Extraovarian Implants in Patients With Ovarian Serous Borderline Tumors (Tumors of Low Malignant Potential) Based on Clinical Outcome.
    McKenney JK; Gilks CB; Kalloger S; Longacre TA
    Am J Surg Pathol; 2016 Sep; 40(9):1155-64. PubMed ID: 27428735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessing the landscape of ovarian serous borderline tumors.
    Messini I; Doulgeraki T; Chrysanthakis D; Yiannou P; Gavresea T; Papadimitriou C; Panoskaltsis T; Voulgaris Z; Vlachos A; Pavlakis K
    Int J Gynecol Cancer; 2019 Mar; 29(3):572-578. PubMed ID: 30659030
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serous borderline tumors of the ovary.
    Prat J
    Adv Clin Path; 1997 Apr; 1(2):97-102. PubMed ID: 10352473
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advanced-stage serous borderline tumors of the ovary: a clinicopathological study of 49 cases.
    Gilks CB; Alkushi A; Yue JJ; Lanvin D; Ehlen TG; Miller DM
    Int J Gynecol Pathol; 2003 Jan; 22(1):29-36. PubMed ID: 12496695
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A nationwide study of ovarian serous borderline tumors in Denmark 1978-2002. Risk of recurrence, and development of ovarian serous carcinoma.
    Hannibal CG; Vang R; Junge J; Frederiksen K; Kurman RJ; Kjaer SK
    Gynecol Oncol; 2017 Jan; 144(1):174-180. PubMed ID: 27836204
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
    Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
    Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinicopathologic analysis of ovarian serous and mucinous borderline tumors].
    Zhong C; Yu X; Zhang J; Wei B; Luo B; Sun L; Zhang N; Fu Q
    Zhonghua Bing Li Xue Za Zhi; 2001 Aug; 30(4):253-5. PubMed ID: 11758211
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pathology of borderline (low malignant potential) ovarian tumours.
    Seidman JD; Ronnett BM; Kurman RJ
    Best Pract Res Clin Obstet Gynaecol; 2002 Aug; 16(4):499-512. PubMed ID: 12413931
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
    Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
    Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pathology of ovarian carcinoma.
    Seidman JD; Kurman RJ
    Hematol Oncol Clin North Am; 2003 Aug; 17(4):909-25, vii. PubMed ID: 12959182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serous borderline (low malignant potential, atypical proliferative) ovarian tumors: workshop perspectives.
    Bell DA; Longacre TA; Prat J; Kohn EC; Soslow RA; Ellenson LH; Malpica A; Stoler MH; Kurman RJ
    Hum Pathol; 2004 Aug; 35(8):934-48. PubMed ID: 15297961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Invasive and noninvasive implants in ovarian serous tumors of low malignant potential.
    Michael H; Roth LM
    Cancer; 1986 Mar; 57(6):1240-7. PubMed ID: 2417697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ovarian serous borderline tumor: the prognostic relation to the pathologic features and management].
    Zhou XR; Du XG
    Zhonghua Fu Chan Ke Za Zhi; 1994 Oct; 29(10):601-3, 637. PubMed ID: 7712874
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic factors for recurrence after conservative treatment in a series of 119 patients with stage I serous borderline tumors of the ovary.
    Uzan C; Muller E; Kane A; Rey A; Gouy S; Bendiffallah S; Duvillard P; Fauvet R; Darai E; Morice P
    Ann Oncol; 2014 Jan; 25(1):166-71. PubMed ID: 24287939
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
    Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of the micropapillary pattern in patients with serous borderline ovarian tumors.
    Chang SJ; Ryu HS; Chang KH; Yoo SC; Yoon JH
    Acta Obstet Gynecol Scand; 2008; 87(4):476-81. PubMed ID: 18382877
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.